Filter Results:
(1,243)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Francis C. Brown
Schering, a German company, was one of the first to be seized by the United States during World War II under the Alien Property Custodian Act. Accepting what he thought was a temporary post, Brown built Schering into a formidable player in the View Details
Keywords: Healthcare
- 24 Apr 2014
- News
A passion for the sea doubles the percent of ocean set aside for conservation
Ernesto Bertarelli (MBA 1993), an America’s Cup–winning sailor and avid scuba diver, understands the importance of protecting marine ecosystems. The former owner and CEO of the pharmaceutical and biotechnology company Serono has provided... View Details
- 01 Jan 2003
- News
Daniel L. Vasella, M.D.
aspirations, purpose, and values, so that they work together as an aligned team." Dan Vasella finds that the skills he called upon as a practicing physician are equally useful in running one of the world's largest pharmaceutical... View Details
- 01 Dec 1998
- News
Novartis AG Establishes Global Research Fund
Four HBS professors whose international research efforts range from biotechnology in Taiwan to foreign investments in Costa Rica have been named the first Novartis Faculty Fellows. The two-year fellowships, funded by a $2 million gift from the worldwide View Details
Keywords: Anne Kavanagh
- 06 May 2008
- First Look
First Look: May 6, 2008
company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing... View Details
Keywords: Martha Lagace
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
Now that scientists have mapped the human gene, can drug makers map a road to unlimited riches? For John Lechleiter, Executive Vice President of Eli Lilly and Company's Pharmaceutical Products and Corporate Development, there remain more... View Details
Keywords: by Sean Silverthorne
- Career Coach
Roshan Tathed
note to Roshan Employment Experience: Duolingo (Internship), Amazon (PM Tech for Amazon Fresh), Strategy& (Strategy consulting); Indian Pharmaceutical Alliance (Project Management); The Walt Disney Company (Internship) View Details
- 24 Apr 2014
- News
Giving hope and inspiration to cancer patients around the globe
Every new day is a good day for Kathryn E. Giusti (MBA 1985) since that morning in 1996 when her oncologist told her to get her affairs in order because she had a rare blood cancer, with three years to live. Leveraging her past experience as a View Details
- 01 Dec 2004
- News
Capitalizing Poetry
Barr Photo courtesy Poetry Foundation In 2002, pharmaceutical heiress Ruth Lilly made a gift in excess of $100 million to the Modern Poetry Association (now the renamed Poetry Foundation). Tapped in February to figure out what to do with... View Details
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
challenges, not on the hard work of winning hearts and minds, Shapiro ultimately lost his company. He was forced to sell Monsanto to Pharmacia-Upjohn, which bought it for its pharmaceutical division, valuing the agricultural biotechnology... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
Arjun Goyal
on the boards of Scorpion Therapeutics, Quanta Therapeutics, Alterome Therapeutics, Halda Therapeutics, Third Arc Bio, and Centessa Pharmaceuticals (NASDAQ: CNTA) and as a co-founder and director, Affini-T Therapeutics. Furthermore, he... View Details
Keywords: Finance
Arjun Goyal
a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Affini-T and Centessa Pharmaceuticals (NASDAQ: CNTA) and has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr... View Details
- 11 Sep 2019
- Research & Ideas
Germany May Have the Answer for Reducing Drug Prices
the Poronui Associate Professor of Business Administration. Pharmaceutical companies have long opposed efforts to regulate drug prices, arguing that prices reflect the companies’ massive research investments. But Germany’s approach shows... View Details
- 15 Dec 2024
- News
After Ozempic
these drugs, known as GLP-1 agonists, amounts to so much more than media buzz. In just a few years, they have ignited a wave of change that has transformed Novo Nordisk into Europe’s most valuable public company. The seismic shift is on track to continue reshaping the... View Details
- 08 Aug 2017
- First Look
First Look at Research and Ideas, August 8, 2017
School Case 415-013 Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A) Over the course of a tumultuous weekend in April 2010, André Wyss was put in charge of Novartis Pharmaceuticals... View Details
Keywords: Sean Silverthorne
- 18 Sep 2014
- News
Room to grow: global expansion in the middle ground
consulting firm Shaldor, documents the specific strategies various companies pursued. As examples, by focusing on a neglected market segment, Netafim became the world leader in drip irrigation technology, while Teva Pharmaceutical created... View Details
- Portrait Project
Mickey Millar
roach. Each incident left a stain on my spirit. While studying social welfare at HKS, I worked part-time so my pregnant sister wouldn't become homeless after she lost her job while on bed rest. During pharmaceutical case discussions at... View Details
- Fast Answer
Patent search: Product-associated patents
face="Open Sans"> Check company website. Some companies may lists patents associated with their products on their websites. For View Details
- Profile
Thomas Grenier
biotech investments. "I showed that it was far more profitable in the United States and that U.S. companies are better at developing new drugs." Thomas will continue to explore health care in his summer internship with Sanofi-Aventis, where he will work on... View Details